# Biohaven Plans Pivotal Trial for Cancer Candidate BHV-1530 by 2027

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/61621
Published: 2026-11-19T19:25:18.000Z
Updated: 2026-11-19T19:25:18.000Z
Section: Business

> The company announced early-stage trial data for the antibody-drug conjugate on Nov. 19.

Biohaven Ltd. (BHVN) shares rose Nov. 19 after the company announced early-stage trial data for cancer candidate BHV-1530 and plans to advance it to a pivotal trial as early as 2027.

BHV-1530 is an antibody-drug conjugate.


